These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 19878640)

  • 1. Supportive therapies in multiple myeloma.
    Gleason C; Nooka A; Lonial S
    J Natl Compr Canc Netw; 2009 Oct; 7(9):971-9. PubMed ID: 19878640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of treatment-related adverse events in patients with multiple myeloma.
    Mateos MV
    Cancer Treat Rev; 2010 May; 36 Suppl 2():S24-32. PubMed ID: 20472185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.
    Delforge M; Bladé J; Dimopoulos MA; Facon T; Kropff M; Ludwig H; Palumbo A; Van Damme P; San-Miguel JF; Sonneveld P
    Lancet Oncol; 2010 Nov; 11(11):1086-95. PubMed ID: 20932799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
    Koeppen S
    Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety of bortezomib for the treatment of multiple myeloma.
    Cengiz Seval G; Beksac M
    Expert Opin Drug Saf; 2018 Sep; 17(9):953-962. PubMed ID: 30118610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of proteasome inhibitor-induced peripheral neuropathy].
    Takamatsu Y
    Nihon Rinsho; 2015 Jan; 73(1):137-41. PubMed ID: 25626319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
    Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
    Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complications of multiple myeloma therapy, part 2: risk reduction and management of venous thromboembolism, osteonecrosis of the jaw, renal complications, and anemia.
    Niesvizky R; Badros AZ
    J Natl Compr Canc Netw; 2010 Feb; 8 Suppl 1():S13-20. PubMed ID: 20141670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thrombotic complications following the treatment of multiple myeloma with new agents].
    Rupa-Matysek J; Gil L; Komarnicki M
    Pol Merkur Lekarski; 2011 Dec; 31(186):372-7. PubMed ID: 22239010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
    Popat R; Brown SR; Flanagan L; Hall A; Gregory W; Kishore B; Streetly M; Oakervee H; Yong K; Cook G; Low E; Cavenagh J;
    Lancet Haematol; 2016 Dec; 3(12):e572-e580. PubMed ID: 27843120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
    Knopf KB; Duh MS; Lafeuille MH; Gravel J; Lefebvre P; Niculescu L; Ba-Mancini A; Ma E; Shi H; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):380-8. PubMed ID: 25023616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events.
    Pérez Persona E; Mesa MG; García Sánchez PJ; González Rodríguez AP
    Adv Ther; 2011 Mar; 28 Suppl 1():11-6. PubMed ID: 21431627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
    Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J
    Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.
    Palumbo A; Gay F
    Hematology Am Soc Hematol Educ Program; 2009; ():566-77. PubMed ID: 20008241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
    Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
    Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma.
    Kumar S; Moreau P; Hari P; Mateos MV; Ludwig H; Shustik C; Masszi T; Spencer A; Hájek R; Romeril K; Avivi I; Liberati AM; Minnema MC; Einsele H; Lonial S; Berg D; Lin J; Gupta N; Esseltine DL; Richardson PG
    Br J Haematol; 2017 Aug; 178(4):571-582. PubMed ID: 28485007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triplet therapies - the new standard of care for multiple myeloma: how to manage common toxicities.
    Paner A; Okwuosa TM; Richardson KJ; Libby EN
    Expert Rev Hematol; 2018 Dec; 11(12):957-973. PubMed ID: 30339769
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathophysiology of drug-induce peripheral neuropathy in patients with multiple myeloma.
    Luczkowska K; Litwinska Z; Paczkowska E; Machalinski B
    J Physiol Pharmacol; 2018 Apr; 69(2):. PubMed ID: 29920472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
    Lazaryan A; Hussein MA; Reu FJ; Faiman B; Habecker B; Ann Karam M; Reed J; Hamilton K; Waksman J; Bruening K; Srkalovic G; Andresen S; Kalaycio M; Sweetenham JW; Sobecks R; Dean R; Knight R; Zeldis JB; Baz R
    Am J Hematol; 2014 Apr; 89(4):349-54. PubMed ID: 24273135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
    Katodritou E; Vadikolia C; Lalagianni C; Kotsopoulou M; Papageorgiou G; Kyrtsonis MC; Matsouka P; Giannakoulas N; Kyriakou D; Karras G; Anagnostopoulos N; Michali E; Briasoulis E; Hatzimichael E; Spanoudakis E; Zikos P; Tsakiridou A; Tsionos K; Anargyrou K; Symeonidis A; Maniatis A; Terpos E
    Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.